Physician profile
Nancy Lam
NPI 1376136614
$2,019.99
in general payments reported to CMS, 2019-2025
26 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $378 · 2022: $756 · 2023: $750 · 2024: $136.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $886.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $885.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $431.51 | 2021-2024 | Ozempic, Rybelsus |
| Amarin Pharma, INC. | $167.49 | 2021-2023 | |
| Pfizer INC. | $155.15 | 2021-2023 | |
| Astrazeneca Pharmaceuticals LP | $154.15 | 2021-2024 | Farxiga, Breztri, Airsupra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $143.63 | 2022-2023 | Jardiance |
| Abbvie INC. | $105.50 | 2021-2024 | |
| Sanofi-Aventis U.S. LLC | $92.38 | 2021-2023 | |
| Dexcom, INC. | $90.45 | 2021-2023 | Dexcom G6 Transmitter |
| Astellas Pharma US INC | $84.04 | 2021-2023 | Veozah, Myrbetriq |
| Xeris Pharmaceuticals, INC. | $80.89 | 2023-2024 | Gvoke Hypopen |
| Amgen INC. | $67.85 | 2022-2023 | Otezla, Repatha, Evenity |
| E.R. Squibb & Sons, L.L.C. | $53.61 | 2022-2024 | Camzyos, Eliquis |
| Kowa Pharmaceuticals America, INC. | $50.07 | 2021-2022 | |
| Glaxosmithkline, LLC. | $49.18 | 2023 | Trelegy Ellipta |
| Bayer Healthcare Pharmaceuticals INC. | $41.97 | 2022 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ironwood Pharmaceuticals, INC | $34.87 | 2022 | |
| Exact Sciences Corporation | $30.74 | 2023 | Cologuard Collection Kit |
| Arbor Pharmaceuticals, INC. | $27.87 | 2021 | |
| Janssen Pharmaceuticals, INC | $26.87 | 2022 | |
| Shield Therapeutics INC | $24.06 | 2023 | |
| Abbott Laboratories | $22.84 | 2021 | |
| Phadia US INC. | $20.34 | 2023 | Immunocap |
| Almatica Pharma LLC | $19.69 | 2022 | |
| Lifescan, INC. | $19.17 | 2023 | |
| Lilly USA, LLC | $15.73 | 2024 | Mounjaro |
| Athena Bioscience, LLC | $9.94 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nancy Lam listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.